Elsa Mondou

4.2k total citations
53 papers, 1.7k citations indexed

About

Elsa Mondou is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Elsa Mondou has authored 53 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Epidemiology, 37 papers in Hepatology and 8 papers in Infectious Diseases. Recurrent topics in Elsa Mondou's work include Hepatitis C virus research (37 papers), Hepatitis B Virus Studies (35 papers) and Liver Disease Diagnosis and Treatment (21 papers). Elsa Mondou is often cited by papers focused on Hepatitis C virus research (37 papers), Hepatitis B Virus Studies (35 papers) and Liver Disease Diagnosis and Treatment (21 papers). Elsa Mondou collaborates with scholars based in United States, France and Canada. Elsa Mondou's co-authors include Franck Rousseau, Robert M. Blum, Herve Momméja-Marin, J. Sorbel, Joseph Quinn, John Bartlett, Michael Fath, Ashwaq Hermes, Ralph DeMasi and David Frederick and has published in prestigious journals such as Gastroenterology, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Elsa Mondou

51 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elsa Mondou United States 19 1.2k 1.0k 382 189 103 53 1.7k
Maria Velez United States 17 415 0.3× 399 0.4× 154 0.4× 26 0.1× 172 1.7× 30 1.2k
Jaume Guàrdia Spain 13 846 0.7× 1.1k 1.0× 91 0.2× 31 0.2× 10 0.1× 17 1.2k
Fernando Carnicer Spain 16 564 0.5× 600 0.6× 103 0.3× 25 0.1× 39 0.4× 31 807
Benjamin Heidrich Germany 21 1.2k 1.0× 1.1k 1.0× 129 0.3× 14 0.1× 30 0.3× 56 1.7k
S. G. Elkington United States 12 287 0.2× 155 0.1× 135 0.4× 158 0.8× 31 0.3× 20 739
L. R. Sutherland Canada 15 304 0.3× 86 0.1× 83 0.2× 26 0.1× 54 0.5× 24 953
Jian‐Wu Yu China 15 452 0.4× 429 0.4× 40 0.1× 10 0.1× 66 0.6× 27 648
Zobair M. Younossi United States 12 1.0k 0.9× 1.1k 1.1× 80 0.2× 6 0.0× 14 0.1× 17 1.6k
Antonio Cuadrado Spain 18 547 0.5× 506 0.5× 73 0.2× 3 0.0× 129 1.3× 61 1.2k
Ksenia Sevastianova Finland 19 1.3k 1.1× 356 0.3× 131 0.3× 143 0.8× 2 0.0× 27 1.8k

Countries citing papers authored by Elsa Mondou

Since Specialization
Citations

This map shows the geographic impact of Elsa Mondou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elsa Mondou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elsa Mondou more than expected).

Fields of papers citing papers by Elsa Mondou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elsa Mondou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elsa Mondou. The network helps show where Elsa Mondou may publish in the future.

Co-authorship network of co-authors of Elsa Mondou

This figure shows the co-authorship network connecting the top 25 collaborators of Elsa Mondou. A scholar is included among the top collaborators of Elsa Mondou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elsa Mondou. Elsa Mondou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Albertí, Joan, et al.. (2022). Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases. International Immunopharmacology. 104. 108472–108472. 3 indexed citations
3.
Karelis, Guntis, Rodica Bălașa, Jan De Bleecker, et al.. (2019). A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. European Neurology. 81(5-6). 223–230. 21 indexed citations
4.
Gelinas, Deborah, et al.. (2019). Myasthenia gravis: Historical achievements and the “golden age” of clinical trials. Journal of the Neurological Sciences. 406. 116428–116428. 23 indexed citations
5.
Kim, Hanna, et al.. (2018). Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified. Clinical Pharmacology Advances and Applications. Volume 10. 79–88. 6 indexed citations
6.
McCallum, Richard W., Anthony Lembo, Tuba Esfandyari, et al.. (2013). Phase 2b, randomized, double‐blind 12‐week studies of TZP ‐102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology & Motility. 25(11). e705–17. 73 indexed citations
7.
Shaw, Monica, et al.. (2013). Safety and Efficacy of Ulimorelin Administered Postoperatively to Accelerate Recovery of Gastrointestinal Motility Following Partial Bowel Resection. Diseases of the Colon & Rectum. 56(7). 888–897. 36 indexed citations
8.
Ejskjær, Niels, John M. Wo, Tuba Esfandyari, et al.. (2012). A phase 2a, randomized, double‐blind 28‐day study of TZP‐102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology & Motility. 25(2). e140–50. 62 indexed citations
9.
Jonas, Maureen M., Déirdre Kelly, Henry Pollack, et al.. (2012). Efficacy and Safety of Long-term Adefovir Dipivoxil Therapy in Children With Chronic Hepatitis B Infection. The Pediatric Infectious Disease Journal. 31(6). 578–582. 15 indexed citations
10.
Marcellin, Patrick, E.J. Heathcote, Thomas Berg, et al.. (2011). 739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES. Journal of Hepatology. 54. S296–S297. 6 indexed citations
11.
Gane, E., E.J. Heathcote, Patrick Marcellin, et al.. (2010). 1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT. Journal of Hepatology. 52. S388–S388. 12 indexed citations
12.
Buti, Marı́a, Stephanos J. Hadziyannis, Philippe Mathurin, et al.. (2008). 75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS. Journal of Hepatology. 48. S33–S33. 5 indexed citations
13.
Wu, I‐Chin, Mitchell L. Shiffman, Myron J. Tong, et al.. (2008). Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants. Clinical Infectious Diseases. 47(10). 1305–1311. 14 indexed citations
14.
Jonas, Maureen M., Déirdre Kelly, Henry Pollack, et al.. (2008). Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 47(6). 1863–1871. 66 indexed citations
15.
Chang, Ting‐Tsung, Myron J. Tong, Piyawat Komolmit, et al.. (2006). Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. Journal of Hepatology. 44. 7 indexed citations
16.
Bartlett, John, Michael Fath, Ralph DeMasi, et al.. (2006). An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 20(16). 2051–2064. 189 indexed citations
17.
Gish, Robert G., Huy N. Trinh, Nancy Leung, et al.. (2005). Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. Journal of Hepatology. 43(1). 60–66. 73 indexed citations
18.
Benson, Constance A., Charles van der Horst, Anthony LaMarca, et al.. (2004). A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS. 18(17). 2269–2276. 42 indexed citations
19.
Marcellin, Patrick, Herve Momméja-Marin, Stephen L. Sacks, et al.. (2004). A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology. 40(1). 140–148. 106 indexed citations
20.
Momméja-Marin, Herve, Elsa Mondou, Robert M. Blum, & Franck Rousseau. (2003). Serum Hbv Dna As A Marker of Efficacy During Therapy for Chronic Hbv Infection: Analysis and Review of the Literature. Hepatology. 37(6). 1309–1319. 223 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Velez Breakdown of academic impact, for papers by Jaume Guàrdia Breakdown of academic impact, for papers by Fernando Carnicer Breakdown of academic impact, for papers by Benjamin Heidrich Breakdown of academic impact, for papers by S. G. Elkington Breakdown of academic impact, for papers by L. R. Sutherland Breakdown of academic impact, for papers by Jian‐Wu Yu Breakdown of academic impact, for papers by Zobair M. Younossi Breakdown of academic impact, for papers by Antonio Cuadrado Breakdown of academic impact, for papers by Ksenia Sevastianova
Rankless by CCL
2026